Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis

Abstract Tumour-stroma ratio (TSR) is a novel potential prognostic factor in cancers and based on the proportions of stroma and tumour area. The prognostic value of TSR in gastric cancer is incompletely known. The aim of this study was to estimate prognostic significance of TSR in gastric adenocarcinoma. A search of PubMed (MEDLINE), Web of Science, EMBASE, Cochrane and Scopus databases was performed. A meta-analysis was conducted on five-year survival in gastric cancer patients using inverse variance random-effects methods. The literature search yielded 5329 potential titles, of which a total of seven studies were eligible. Results of six studies including a total of 1779 patients were pooled in the meta-analysis. Only 23 (1.3%) of the patients received neoadjuvant therapy. All six studies had a cut-off of 50% for the proportion of stroma when dividing the patients into low- and high stroma groups. Low TSR (high amount of stroma) was strongly associated with increased five-year mortality (hazard ratio 2.19, 95% CI 1.69–2.85). In conclusion, TSR is a strong prognostic factor in gastric cancer. It could be used to estimate prognosis of gastric cancer patients not receiving neoadjuvant chemotherapy. Further studies including patients receiving neoadjuvant therapy are recommended.

Download Full-text

The Clinicopathological and Prognostic Significance of IDO1 Expression in Human Solid Tumors: Evidence from a Systematic Review and Meta-Analysis

Cellular Physiology and Biochemistry ◽

10.1159/000492849 ◽

2018 ◽

Vol 49 (1) ◽

pp. 134-143 ◽

Cited By ~ 18

Author(s):

Cheng-Peng Yu ◽

Shu-Fang Fu ◽

Xuan Chen ◽

Jing Ye ◽

Yuan Ye ◽

...

Keyword(s):

Systematic Review ◽

Cancer Patients ◽

Solid Tumors ◽

Meta Analysis ◽

Prognostic Significance ◽

High Expression ◽

Cochrane Library ◽

Odds Ratios ◽

Ido1 Expression ◽

Human Solid Tumors

Background/Aims: Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing enzyme catalyzing the initial and rate-limiting steps in the kynurenine pathway, which converts tryptophan into kynurenine. Upregulation of IDO1 decreases tryptophan levels and increases the accumulation of kynurenine and its metabolites. These metabolites can affect the proliferation of T cells. Increasing evidence has shown that IDO1 is highly expressed in various cancer types and associated with poor prognosis of cancer patients. However, the results were inconsistent. Methods: We searched the Web of Science, PubMed, Embase and Cochrane library databases to identify studies evaluating the prognostic value of IDO1 in cancer patients. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by using fixed-effects/random-effects models. Results: This systematic review and meta-analysis included 2706 patients from 24 articles. The results indicated a shorter overall survival in patients with high expression of IDO1 (hazard ratio [HR] = 2.03, 95% confidence interval [CI]: 1.56-2.63). Furthermore, disease-free survival was worse in patients with high expression of IDO1 (HR = 2.47, 95% CI: 1.46-4.20). Additionally, the pooled odds ratios (ORs) showed that increased IDO1 was significantly associated with tumor differentiation (OR = 1.81, 95% CI: 1.05-3.12), distant metastasis (OR = 1.45, 95% CI: 1.02-2.06), and poor clinical stage (OR = 1.89, 95% CI: 1.13-3.17). However, no significant correlation was observed of increased IDO1 expression with age, sex, lymph node metastasis, and tumor size. Conclusion: High expression of IDO1 is associated with poor clinical outcomes. IDO1 could serve as a biomarker of prognosis and a potential predictive factor of clinicopathology in various cancers. Further studies should be performed to verify the clinical utility of IDO1 in human solid tumors.

Download Full-text

Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma

Journal of Clinical Oncology ◽

10.1200/jco.2001.19.16.3660 ◽

2001 ◽

Vol 19 (16) ◽

pp. 3660-3668 ◽

Cited By ~ 294

Author(s):

Stephen K. Chia ◽

Charles C. Wykoff ◽

Peter H. Watson ◽

Cheng Han ◽

Russell D. Leek ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Breast Carcinoma ◽

Carbonic Anhydrase ◽

Invasive Breast Cancer ◽

Estrogen Receptor Status ◽

Prognostic Significance ◽

Invasive Breast Carcinoma ◽

Carbonic Anhydrase Ix ◽

Ca Ix

PURPOSE: To assess the frequency of expression and the prognostic significance of a hypoxia-regulated marker, carbonic anhydrase IX (CA IX), in a cohort of patients with invasive breast cancer. PATIENTS AND METHODS: CA IX expression was evaluated by immunohistochemistry with a murine monoclonal antibody, M75, in a series of 103 women treated surgically for invasive breast cancer. The majority of patients were treated with adjuvant hormonal or chemotherapy. The frequency of CA IX expression, its association with recognized prognostic factors, and the relationship with outcome was evaluated by univariate and multivariate statistical analyses. RESULTS: CA IX expression was present in 49 (48%) of 103 cases. The level of CA IX expression was found to be significantly associated with tumor necrosis (P < .001), higher grade (P = .02), and negative estrogen receptor status (P < .001). Furthermore, CA IX expression was associated with a higher relapse rate (P = .004) and a worse overall survival (P = .001). By multivariate analysis, CA IX was also shown to be an independent predictive factor for overall survival (hazard ratio, 2.61; 95% confidence interval, 1.01 to 6.75, P = .05). CONCLUSION: CA IX expression was associated with worse relapse-free survival and overall survival in an unselected cohort of patients with invasive breast carcinoma. The potential role of CA IX as a marker of hypoxia within breast carcinomas was also indicated by a significant association with necrosis. Further work assessing its prognostic significance in breast cancer is warranted, particularly interactions with radiotherapy and chemotherapy resistance.

Download Full-text

Prognostic significance of 18FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis

Cancer Imaging ◽

10.1186/s40644-015-0055-z ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 39

Author(s):

Qian Xia ◽

Jianjun Liu ◽

Cheng Wu ◽

Shaoli Song ◽

Linjun Tong ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Cancer Patients ◽

Meta Analysis ◽

Prognostic Significance ◽

18Fdg Pet ◽

Pet Ct ◽

Colorectal Cancer Patients

Download Full-text

Prognostic Significance of High Survivin Expression in Patients with Gastrointestinal Cancer: A Meta-Analysis

10.20944/preprints201704.0062.v1 ◽

2017 ◽

Author(s):

Pingping Xu ◽

Jiajia Lin ◽

Qi Lin ◽

Dexiang Zhu ◽

Wentao Tang ◽

...

Keyword(s):

Cancer Patients ◽

Meta Analysis ◽

Prognostic Significance ◽

Survivin Expression ◽

Disease Free Survival ◽

Cochrane Library ◽

Prognostic Impact ◽

Gi Cancer ◽

Literature Searches ◽

The Cochrane Library

Previous studies on the prognostic impact of survivin expression in gastrointestinal (GI) cancer have yielded inconsistent results. This study was initiated to assess the relationship between survivin expression and overall survival (OS) or disease free survival (DFS) in GI cancer patients. We applied system literature searches on EMBASE, PubMed, Web of science, and the Cochrane library to conduct this up-to-date meta-analysis. Thirty studies with totally 3622 GI cancer patients were collected. The prevalence of high survivin expression in GI cancer was 0.57 (95% CI: 0.51-0.63). High survivin expression was significantly associated with shorter OS (HR 1.57, 95% CI: 1.42-1.74) and DFS (HR 1.38, 95% CI: 1.21-1.58). Subgroup analysis also showed significant association between high survivin expression and poorer OS or DFS in gastric cancer or colorectal cancer. In summary, our study indicated that high survivin expression was related to poor prognosis in GI cancer. Well-designed studies with large sample and more convincing data are needed to confirm our conclusion.

Download Full-text